FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987831211> ?p ?o ?g. }

• W2987831211 endingPage "e1098" @default.
• W2987831211 startingPage "e1090" @default.
• W2987831211 abstract "The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) on the rates of patient-oriented composite endpoints (POCE) and net adverse clinical events (NACE).The rates of site-reported Academic Research Consortium (ARC)-2 defined POCE (all-cause death, any stroke, any myocardial infarction or any revascularisation) and NACE (POCE or bleeding type 3 or 5 according to the Bleeding ARC [BARC]) were reported up to two years by intention-to-treat principle in the randomised, multicentre, open-label GLOBAL LEADERS study comparing two antiplatelet strategies in 15,991 patients undergoing PCI. The experimental strategy consisted of aspirin with ticagrelor for one month followed by ticagrelor monotherapy for 23 months, whereas the reference treatment consisted of 12-month DAPT followed by 12-month aspirin monotherapy. At two years, POCE occurred in 1,050 (13.2%) patients in the experimental group and in 1,131 (14.2%) in the reference group (HR 0.93, 95% CI: 0.85-1.01, p=0.085). NACE occurred in 1,145 (14.4%) patients in the experimental group and in 1,237 (15.5%) patients in the reference group (HR 0.92, 95% CI: 0.85-1.00, p=0.057). In pre-specified subgroup analyses, no significant treatment-by-subgroup interactions were found for either POCE or NACE at two years.The experimental treatment strategy of one-month DAPT followed by 23 months of ticagrelor alone did not result in a significant reduction in the rates of site-reported POCE or NACE, when compared to the reference treatment. ClinicalTrials.gov Identifier: NCT01813435." @default.
• W2987831211 created "2019-11-22" @default.
• W2987831211 creator A5003578699 @default.
• W2987831211 creator A5010936003 @default.
• W2987831211 creator A5026031312 @default.
• W2987831211 creator A5031006058 @default.
• W2987831211 creator A5038409870 @default.
• W2987831211 creator A5040217641 @default.
• W2987831211 creator A5042853338 @default.
• W2987831211 creator A5045815190 @default.
• W2987831211 creator A5047707907 @default.
• W2987831211 creator A5049653560 @default.
• W2987831211 creator A5059011787 @default.
• W2987831211 creator A5060727278 @default.
• W2987831211 creator A5061620221 @default.
• W2987831211 creator A5063247968 @default.
• W2987831211 creator A5063792624 @default.
• W2987831211 creator A5063859581 @default.
• W2987831211 creator A5066220853 @default.
• W2987831211 creator A5069601173 @default.
• W2987831211 creator A5073840451 @default.
• W2987831211 creator A5080398218 @default.
• W2987831211 creator A5080770746 @default.
• W2987831211 creator A5084631056 @default.
• W2987831211 creator A5087700658 @default.
• W2987831211 date "2019-12-01" @default.
• W2987831211 modified "2023-10-14" @default.
• W2987831211 title "Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial" @default.
• W2987831211 cites W1910511103 @default.
• W2987831211 cites W1990664285 @default.
• W2987831211 cites W2013106394 @default.
• W2987831211 cites W2030531780 @default.
• W2987831211 cites W2046277322 @default.
• W2987831211 cites W2087682588 @default.
• W2987831211 cites W2100953281 @default.
• W2987831211 cites W2146514939 @default.
• W2987831211 cites W2169252265 @default.
• W2987831211 cites W2342318753 @default.
• W2987831211 cites W2399554534 @default.
• W2987831211 cites W2593571361 @default.
• W2987831211 cites W2792588444 @default.
• W2987831211 cites W2808359328 @default.
• W2987831211 cites W2809722890 @default.
• W2987831211 cites W2886195982 @default.
• W2987831211 cites W2888458270 @default.
• W2987831211 cites W2900406919 @default.
• W2987831211 doi "https://doi.org/10.4244/eij-d-19-00202" @default.
• W2987831211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30888959" @default.
• W2987831211 hasPublicationYear "2019" @default.
• W2987831211 type Work @default.
• W2987831211 sameAs 2987831211 @default.
• W2987831211 citedByCount "16" @default.
• W2987831211 countsByYear W29878312112019 @default.
• W2987831211 countsByYear W29878312112020 @default.
• W2987831211 countsByYear W29878312112021 @default.
• W2987831211 countsByYear W29878312112022 @default.
• W2987831211 crossrefType "journal-article" @default.
• W2987831211 hasAuthorship W2987831211A5003578699 @default.
• W2987831211 hasAuthorship W2987831211A5010936003 @default.
• W2987831211 hasAuthorship W2987831211A5026031312 @default.
• W2987831211 hasAuthorship W2987831211A5031006058 @default.
• W2987831211 hasAuthorship W2987831211A5038409870 @default.
• W2987831211 hasAuthorship W2987831211A5040217641 @default.
• W2987831211 hasAuthorship W2987831211A5042853338 @default.
• W2987831211 hasAuthorship W2987831211A5045815190 @default.
• W2987831211 hasAuthorship W2987831211A5047707907 @default.
• W2987831211 hasAuthorship W2987831211A5049653560 @default.
• W2987831211 hasAuthorship W2987831211A5059011787 @default.
• W2987831211 hasAuthorship W2987831211A5060727278 @default.
• W2987831211 hasAuthorship W2987831211A5061620221 @default.
• W2987831211 hasAuthorship W2987831211A5063247968 @default.
• W2987831211 hasAuthorship W2987831211A5063792624 @default.
• W2987831211 hasAuthorship W2987831211A5063859581 @default.
• W2987831211 hasAuthorship W2987831211A5066220853 @default.
• W2987831211 hasAuthorship W2987831211A5069601173 @default.
• W2987831211 hasAuthorship W2987831211A5073840451 @default.
• W2987831211 hasAuthorship W2987831211A5080398218 @default.
• W2987831211 hasAuthorship W2987831211A5080770746 @default.
• W2987831211 hasAuthorship W2987831211A5084631056 @default.
• W2987831211 hasAuthorship W2987831211A5087700658 @default.
• W2987831211 hasConcept C126322002 @default.
• W2987831211 hasConcept C127413603 @default.
• W2987831211 hasConcept C141071460 @default.
• W2987831211 hasConcept C168563851 @default.
• W2987831211 hasConcept C187960798 @default.
• W2987831211 hasConcept C197934379 @default.
• W2987831211 hasConcept C203092338 @default.
• W2987831211 hasConcept C2777628954 @default.
• W2987831211 hasConcept C2777698277 @default.
• W2987831211 hasConcept C2780400711 @default.
• W2987831211 hasConcept C2780645631 @default.
• W2987831211 hasConcept C2780890252 @default.
• W2987831211 hasConcept C44249647 @default.
• W2987831211 hasConcept C45393284 @default.
• W2987831211 hasConcept C500558357 @default.
• W2987831211 hasConcept C535046627 @default.
• W2987831211 hasConcept C71924100 @default.
• W2987831211 hasConcept C78519656 @default.

• next